Role of DNA repair machinery and p53 in the testicular germ cell cancer: A review

Oncotarget

Volumn 7, Issue 51, 2016, Pages 85641-85649

  Romano, Francesco Jacopo ^a   Rossetti, Sabrina ^a,b   Conteduca, Vincenza ^c   Schepisi, Giuseppe ^c   Cavaliere, Carla ^a,d   Di Franco, Rossella ^a,b   La Mantia, Elvira ^a,b   Castaldo, Luigi ^a,b   Nocerino, Flavia ^b   Ametrano, Gianluca ^a,b   Cappuccio, Francesca ^a,b   Malzone, Gabriella ^a,b   Montanari, Micaela ^a,e   Vanacore, Daniela ^a   Quagliariello, Vincenzo ^a   Piscitelli, Raffaele ^a,b   Pepe, Maria Filomena ^a,b   Berretta, Massimiliano ^f   D'Aniello, Carmine ^a,g   Perdonà, Sisto ^b   Muto, Paolo ^b   Botti, Gerardo ^b   Ciliberto, Gennaro ^b   Veneziani, Bianca Maria ^e   De Falco, Francesco ^b   Maiolino, Piera ^b   Caraglia, Michele ^h   Montella, Maurizio ^b   De Giorgi, Ugo ^c   Facchini, Gaetano ^a,b   more..

^a Diagnosi precoce del tumore alla prostata e testicolo ^*  (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^d S G MOSCATI HOSPITAL   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^g MONALDI HOSPITAL   (Italy)

^h SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

ATM; DDR; Germ cell cancer; P53; Testis

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN; AZD 0156; CARBOPLATIN; CISPLATIN; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; VELIPARIB; MDM2 PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; TP53 PROTEIN, HUMAN;

APOPTOSIS; CANCER RESISTANCE; CELL FATE; CHEMOSENSITIVITY; CLINICAL TRIAL (TOPIC); DNA DAMAGE; DNA REPAIR; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MUTATION; GENETIC VARIABILITY; GERM CELL CANCER; HOMOLOGOUS RECOMBINATION; HUMAN; MDM2 GENE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE; ANIMAL; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MALE; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION; TESTIS TUMOR;

ANIMALS; CISPLATIN; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MDM2; SIGNAL TRANSDUCTION; TESTICULAR NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85007478185     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.13063     Document Type: Review

References (62)

1. Hardell L, Bavel B, Lindström G, Eriksson M, Carlberg M. In utero exposure to persistent organic pollutants in relation to testicular cancer risk. Int J Androl. 2006 Feb;29:228-34. Epub 2005 Dec 20.
2. Hardell L, Van Bavel B, Lindström G, Carlberg M, Eriksson M, Dreifaldt AC, Wijkström H, Starkhammar H, Hallquist A, Kolmert T. Concentrations of polychlorinated biphenyls in blood and the risk for testicular cancer. Int J Androl. 2004 Oct;27:282-90.
3. Di Pietro A, Vries EG, Gietema JA, Spierings DC, de Jong S. Testicular germ cell tumors: the paradigm of chemosensitive solid tumors. Int. J. Biochem. Cell Biol. 37, 2437-2456 (2005).
4. Looijenga LH, Gillis AJ, Stoop H, Biermann K, Oosterhuis JW. Dissecting the molecular pathways of testicular germ cell tumor pathogenesis; from initiation to treatmentresistance. Int. J. Androl. 34, e234-e251 (2011).
5. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J. Clin. Oncol. 15, 594-603 (1997).
6. Hanna NH, Einhorn LH. Testicular cancer-discoveries and updates. N Engl J Med. 2014;371:2005-16.
7. Gori S, Porrozzi S, Roila F, Gatta G, De Giorgi U, Marangolo M. Germ cell tumours of the testis. Critical Reviews in Oncology/Hematology 2005; 53:141-164.
8. Olivier M, Hollstein M, Hainaut P. TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use Cold Spring Harb Perspect Biol. 2010 Jan; 2: a001008.
9. Lutzker SG. p53 tumour suppressor gene and germ cell neoplasia APMIS 106: 85-89. 1998.
10. Takami H, Yoshida A, Fukushima S, Arita H, Matsushita Y, Nakamura T, Ohno M, Miyakita Y, Shibui S, Narita Y, Ichimura K. Revisiting TP53 Mutations and Immunohistochemistry-A Comparative Study in 157 Diffuse Gliomas Brain Pathology 25 (2015) 256-265.
11. Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih IeM, Kurman RJ. Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis. Mod Pathol. 2011 Sep;24:1248-53. doi: 10.1038/modpathol.2011.85.
12. Guillou L, Estreicher A, Chaubert P, Hurlimann J, Kurt AM, Metthez G, Iggo R, Gray AC, Jichlinski P, Leisinger HJ, Benhattar J. Germ cell tumors of the testis overexpress wild-type p53, Am. J. Pathol. 149 (1996) 1221-1228.
13. Schenkman, NS, Sesterhenn IA, Washington L, Tong YA, Weghorst CM, Buzard GS, Srivastava S, Moul JW. Increased p53 Protein Does Not Correlate to p53 Gene Mutations in Microdissected Human Testicular Germ Cell Tumors The Journal of Urology, Volume 154, Issue 2, 617-621.
14. Gutekunst M, Oren M, Weilbacher A, Dengler MA, Markwardt C, Thomale J, Aulitzky WE, van der Kuip H., et al. p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin, PLoS ONE 6 (2011) e19198.
15. De Giorgi U, Yuan J, Moroni M, Veronese S, Sartore-Bianchi A, Broggini M, Rosti G, Strebhardt K, Ruffini PA. Germ cell tumors overexpress the candidate therapeutic target cyclin B1 independently of p53 function. Int J Biol Markers. 2015;30:e275-81.
16. Burger H, Nooter K, Boersma AW, Kortland CJ, Stoter G. Lack of correlation between cisplatin-induced apoptosis, p53 status and expression of Bcl-2 family proteins in testicular germ cell tumour cell lines. Int J Cancer. 1997 Nov 14;73:592-9.
17. Kersemaekers AM, Mayer F, Molier M, van Weeren PC, Oosterhuis JW, Bokemeyer C, Looijenga LH. Role of p53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol. 2002 Mar 15;20:1551-61.
18. Boublikova L, Bakardjieva-Mihaylova V, Skvarova Kramarzova K, Kuzilkova D, Dobiasova A, Fiser K, Stuchly J, Kotrova M, Buchler T, Dusek P, Grega M, Rosova B, Vernerova Z. et al. Wilms tumor gene 1 (WT1), TP53, RAS/BRAF and KIT aberrations in testicular germ cell tumors Cancer Lett. 2016 Jul 1;376:367-76.
19. Honda R Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997 Dec 22;420:25-7.
20. Oliver RT, Shamash J, Berney DM. p53 and MDM2 in germ cell cancer treatment response. J Clin Oncol. 2002 Sep 15;20:3928; author reply 3928-9.
21. Landers JE, Cassel SL, George DL. Translational enhancement of mdm2 oncogene expression in human tumor cells containing a stabilized wild-type p53 protein. Cancer Res. 1997 Aug 15;57:3562-8.
22. Berberich S, Cole M. The mdm-2 oncogene is translocated and overexpressed in a murine plasmacytoma cell line expressing wild-type p53. Oncogene. 1994 May;9:1469-72.
23. Eid H, Institoris E, Géczi L, Bodrogi I, Bak M.mdm-2 expression in human testicular germ-cell tumors and its clinical value Anticancer Res. 1999 Jul-Aug;19(4C):3485-90.
24. Li B, Cheng Q, Li Z, Chen J. p53 inactivation by MDM2 and MDMX negative feedback loops in testicular germ cell tumors. Cell Cycle. 9:7, 1411-1420; April 1, 2010.
25. Koster R, Timmer-Bosscha H, Bischoff R, Gietema JA, de Jong S. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway. Cell Death Dis. 2011 Apr 21;2:e148. doi: 10.1038/cddis.2011.33.
26. Bagrodia A, Lee BH, Lee W, Cha EK, Sfakianos JP, Iyer G, Pietzak EJ, Gao SP, Zabor EC, Ostrovnaya I, Kaffenberger SD, Syed A, Arcila ME. et al. Genetic Determinants of Cisplatin Resistance in Patients With Advanced Germ Cell Tumors. J Clin Oncol. 2016 Sep 19. pii: JCO687798. [Epub ahead of print].
27. De Giorgi U, Rosti G, Slavin S, Yaniv I, Harousseau JL, Ladenstein R, Demirer T, Dini G. Salvage high-dose chemotherapy for children with extragonadal germ-cell tumours. Br J Cancer 2005; 93: 412-417.
28. Lorch A, Bascoul-Mollevi C, Kramar A, Einhorn L, Necchi A, Massard C, De Giorgi U, Fléchon A, Margolin K, Lotz JP, Germà-Lluch JR, Powles T, Kollmannsberger C, et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol. 2011 Jun 1;29:2178-84. doi: 10.1200/JCO.2010.32.6678. Epub 2011 Mar 28.
29. De Giorgi U, Demirer T, Wandt H, Taverna C, Siegert W, Bornhauser M, Kozak T, Papiani G, Ballardini M, Rosti G. Second-line high-dose chemotherapy in patients with mediastinal and retroperitoneal primary non-seminomatous germ cell tumors: the EBMT experience. Ann Oncol. 2005 Jan;16:146-51.
30. Einhorn LH, Williams SD, Chamness A, Brames MJ, Perkins SM, Abonour R. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors. N Engl J Med. 2007 Jul 26;357:340-8.
31. De Giorgi U, Rosti G, Papiani G, Marangolo M. The status of high-dose chemotherapy with hematopoietic stem cell transplantation in germ cell tumor patients. Haematologica 2002; 87 (1), 95-104.
32. Köberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR. DNA repair capacity and cisplatin sensitivity of human testis tumor cells Int J Cancer. 1997 Mar 4;70:551-5.
33. Cavallo F, Graziani G, Antinozzi C, Feldman DR, Houldsworth J, Bosl GJ, Chaganti RS, Moynahan ME, Jasin M, Barchi M. Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition. PLoS One. 2012;7:e51563. doi: 10.1371/journal.pone.0051563. Epub 2012 Dec 12.
34. Bartkova J, Bakkenist CJ, Rajpert-De Meyts E, Skakkebaek NE, Sehested M, Lukas J, Kastan MB, Bartek J. ATM Activation in Normal Human Tissues and Testicular Cancer Cell Cycle. 2005 Jun;4:838-45. Epub 2005 Jun 13.
35. Di Tullio RA Jr, Mochan TA, Venere M, Bartkova J, Sehested M, Bartek J, Halazonetis TD. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol. 2002 Dec;4:998-1002.
36. Bartkova J, Guldberg P, Grønbaek K, Koed K, Primdahl H, Møller K, Lukas J, Ørntoft TF, Bartek J.Aberrations of the Chk2 tumor suppressor in advanced urinary bladder cancer. Oncogene. 2004 Nov 4;23:8545-51.
37. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005 Apr 14;434:907-13.
38. Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Ørntoft T, Lukas J, Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005 Apr 14;434:864-70.
39. Bartkova J, Hoei-Hansen CE, Krizova K, Hamerlik P, Skakkebæk NE, Rajpert-De Meyts E, Bartek J. Patterns of DNA damage response in intracranial germ cell tumors versus glioblastomas reflect cell of origin rather than brain environment: Implications for the anti-tumor barrier concept and treatment. Mol Oncol. 2014 Dec;8:1667-78. doi: 10.1016/j.molonc.2014.07.001. Epub 2014 Jul 9.
40. Gigantino V, La Mantia E, Franco R, Cecere S, Rossetti S, Di Napoli M, Pisano C, Berretta M, Galzerano A, Botti G, Pignata S, Facchini G. Testicular and testicular adnexa tumors in the elderly. Anticancer Drugs. 2013 Mar;24:228-36.
41. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005 Apr 14;434:907-13.
42. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, Schurra C, Garre' M, Nuciforo PG, Bensimon A, Maestro R, Pelicci PG, d'Adda di Fagagna F. Oncogene induced senescence is a DNA damage response triggered by DNA hyper replication. Nature. 2006 Nov 30;444:638-42.
43. Rezaee M, Sanche L, Hunting DJ. Cisplatin enhances the formation of DNA single-and double-strand breaks by hydrated electrons and hydroxyl radicals. Radiat Res. 2013 Mar;179:323-31. doi: 10.1667/RR3185.1. Epub 2013 Jan 31.
44. Richardson C, Moynahan ME, Jasin M. Double-strand break repair by interchromosomal recombination: suppression of chromosomal translocations. Genes Dev. 1998 Dec 15;12:3831-42.
45. Richardson C, Jasin M. Frequent chromosomal translocations induced by DNA double-strand breaks. Nature. 2000 Jun 8;405:697-700.
46. Helleday T. Homologous recombination in cancer development, treatment and development of drug resistance Carcinogenesis. 2010 Jun;31:955-60. doi: 10.1093/carcin/bgq064. Epub 2010 Mar 29.
47. Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, Mok SC, D'Andrea AD. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003 May;9:568-74. Epub 2003 Apr 7.
48. Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R. CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res. 2005 Oct 1;65:8961-7.
49. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, Villegas E, Jacquemont C, Farrugia DJ, Couch FJ, Urban N, Taniguchi T. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008 Feb 28;451:1116-20. doi: 10.1038/nature06633. Epub 2008 Feb 10.
50. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A. Resistance to therapy caused by intragenic deletion in BRCA2. Nature. 2008 Feb 28;451:1111-5. doi: 10.1038/nature06548. Epub 2008 Feb 10.
51. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 2008 Apr 15;68:2581-6. doi: 10.1158/0008-5472.CAN-08-0088.
52. Hansen LT, Lundin C, Spang-Thomsen M, Petersen LN, Helleday T. The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer. Int J Cancer. 2003 Jul 1;105:472-9.
53. Hansen LT, Lundin C, Helleday T, Poulsen HS, Sørensen CS, Petersen LN, Spang-Thomsen M. DNA repair rate and etoposide (VP16) resistance of tumor cell subpopulations derived from a single human small cell lung cancer. Lung Cancer. 2003 May;40:157-64.
54. Westphal CH, Hoyes KP, Canman CE, Huang X, Kastan MB, Hendry JH, Leder P. Loss of ATM radiosensitizes multiple p53 Null Tissues Cancer Res. 1998 Dec 15;58:5637-9.
55. Fedier A, Schlamminger M, Schwarz VA, Haller U, Howell SB, Fink D. Loss of atm sensitises p53-deficient cells to topoisomerase poisons and antimetabolites. Ann Oncol. 2003 Jun;14:938-45.
56. Toulany M, Mihatsch J, Holler M, Chaachouay H, Rodemann HP. Cisplatin-mediated radiosensitization of non-small cell lung cancer cells is stimulated by ATM inhibition Radiother Oncol. 2014 May;111:228-36. doi: 10.1016/j.radonc.2014.04.001. Epub 2014 May 21.
57. Guo W, Ahmed KM, Hui Y, Guo G, Li JJ. siRNA-mediated MDM2 inhibition sensitizes human lung cancer A549 cells to radiation Int J Oncol. 2007 Jun;30:1447-52.
58. Zheng M, Yang J, Xu X, Sebolt JT, Wang S, Sun Y. Efficacy of MDM2 Inhibitor MI-219 Against Lung Cancer Cells Alone or in Combination with MDM2 Knockdown, a XIAP Inhibitor or Etoposide Anticancer Res. 2010 Sep;30:3321-31.
59. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev. 2009 Aug 15;23:1895-909. doi: 10.1101/gad.1815309. Epub 2009 Jul 16.
60. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010 Feb;2:a001107. doi: 10.1101/cshperspect.a001107.
61. Zhang Y, Coillie SV, Fang JY, Xu J. Gain of function of mutant p53: R282W on the peak? Oncogenesis. 2016 Feb 15;5:e196. doi: 10.1038/oncsis.2016.8.
62. Mego M, Cierna Z, Svetlovska D, Macak D, Machalekova K, Miskovska V, Chovanec M, Usakova V, Obertova J, Babal P, Mardiak J. PARP expression in germ cell tumours. J Clin Pathol. 2013 Jul;66:607-12. doi: 10.1136/jclinpath-2012-201088. Epub 2013 Mar 13.